Evaluation of Serum Soluble Endoglin Levels in Pre-eclampsia: A Case-Control Study

Sawarkar, Yuganti C and Agarwal, Rachna and Mehndiratta, Mohit and Suneja, Amita and Aggarwal, Richa (2023) Evaluation of Serum Soluble Endoglin Levels in Pre-eclampsia: A Case-Control Study. JOURNAL OF CLINICAL AND DIAGNOSTIC RESEARCH, 17 (2). QC18-QC23. ISSN 2249782X

[thumbnail of 57711_CE[Ra1]_F(IS)_PF1(AKA_SS)_PFA(AKA_KM)_PN(KM).pdf] Text
57711_CE[Ra1]_F(IS)_PF1(AKA_SS)_PFA(AKA_KM)_PN(KM).pdf - Published Version

Download (453kB)

Abstract

Introduction: Soluble Endoglin (sEng) has an antiangiogenic effect, by inhibiting of Transforming Growth Factor (TGF)-β1 bond at endoglin receptors and inhibiting vasodilatation. sEng levels increase in Pre-eclampsia (PE) due to hypoxic placenta and there have been possible role of it in the pathogenesis of PE and its therapeutic implications.

Aim: To compare serum sEng levels in pre-eclamptic patients (cases) versus control.

Materials and Methods: This case-control study was carried out November 2019 to October 2021, in the Department of Obstetrics and Gynaecology, University College of Medical Sciences, Delhi. On 40 cases with a singleton pregnancy with diagnosis of PE enrolled as cases and 40 normal healthy pregnant women matched for age and gestational age as controls. sEng was estimated using commercially available Enzyme- Linked Immunosorbent Assay (ELISA) kit. Last uterine (Ut) and Umbilical Artery (UA) doppler findings were noted and sEng levels were compared with doppler studies. The analysis was done using student t-test and Chi-square test.

Results: A total of 80 participants were included in the study, 40 in case group (mean age 26.53±4.93 years) and 40 in control group (mean age: 25.35±3.10 years). A total of 21 PE cases were Non Severe PE (NSPE) (52.5%) and 19 were Severe PE (SPE) (47.5%). Early-onset PE was observed in n=11 (28%) and the remaining n=29 (72%) had late-onset PE. sEng was significantly higher in pre-eclamptic women 55.08±21.42 ng/mL as compared to controls 44.15±12.02 ng/mL (p=0.006). Higher levels of sEng were seen in SPE 59.20±28.44 ng/mL vs NSPE 51.36±11.66 ng/mL (p=0.066). sEng levels between early onset PE (50.93±5.89 ng/mL) and late onset PE (56.66±24.84 ng/mL) (p=0.832). sEng levels were higher in cases with abnormal Resistance Index (RI) of Ut artery 54.23±6.68 ng/mL than in normal RI of Ut artery 54.23±6.68 ng/mL, though not significant. Abnormal Ut artery RI doppler was seen more in early-onset (n=2, 33%) than in late onset PE (n=1, 7%).

Conclusion: The PE cases had significantly higher levels of sEng compared to controls. Thus, it can be concluded that, there is a definitive role of sEng in pathogenesis of PE due to its antiangiogenic action.

Item Type: Article
Subjects: GO STM Archive > Medical Science
Depositing User: Unnamed user with email support@gostmarchive.com
Date Deposited: 17 Jun 2023 07:04
Last Modified: 14 Sep 2024 04:11
URI: http://journal.openarchivescholar.com/id/eprint/1133

Actions (login required)

View Item
View Item